Pipeline
EU301
|
Indication
B-cell precursor ALL Diffuse large B-cell lymphoma (DLBCL) |
Target /Drug class HLA-DR expressing cancer cell / CAR-T | Development Stage Non-clinical |
Summary
- MVR CAR-T can be used against HLA-DR positive cancer, as well as B cell malignancy.
- The epitopes recognized by HLA-DR are not shed or internalized, enabling stable binding to human lymphoma cells.
- MVR CAR-T can also be used in patients who relapse after CD19 CAR-T treatment.
- Reduction of cytokine secretion due to selective killing of tumor cells.
in vivo Efficacy
